Enovis

Enovis EV/FCF

The EV/FCF (Enterprise Value to Free Cash Flow) of Enovis (ENOV) as of Oct 15, 2026 is 127.04. In the previous year, EV/FCF (Enterprise Value to Free Cash Flow) was -37.59 — a change of -437.96% (higher).

EV/FCF

127.04

YoY

-437.96%

Last updated:

EV/FCF (Enterprise Value to Free Cash Flow) of Enovis is 2025 127.04 . EV/FCF (Enterprise Value to Free Cash Flow) of Enovis was 2024 -37.59 . It decreases by -437.96% higher compared to the previous year.

The Enovis EV/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/FCF
Date
EV/FCF
Jan 1, 2018
14.02 USD
Jan 1, 2019
621.57 USD
Jan 1, 2020
18.03 USD
Jan 1, 2021
10.53 USD
Jan 1, 2022
-9.17 USD
Jan 1, 2023
131.22 USD
Jan 1, 2024
-37.59 USD
Jan 1, 2025
127.04 USD
The Enovis EV/FCF history
YEAREV/FCFYoY
127.04-437.96%
-37.59-128.65%
131.22-1,530.19%
-9.17-187.16%
10.53-41.63%
18.03-97.10%
621.57+4,333.04%
14.02+11.02%
12.63+0.21%
12.60+179.90%
4.50+44.37%
3.12—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Enovis Stock analysis

What does Enovis do? Enovis Corp, listed on the stock market with ticker ENOV and ISIN US1940145022, is a health care company headquartered in Wilmington, United States. The company has 7,802 employees and went public on May 8, 2008. Enovis operates within the health care sector, focusing on medical technology and the development of clinically differentiated solutions. The company manufactures and distributes medical devices used in reconstructive surgery, rehabilitation, pain management, and physical therapy. It functions through two operational segments: Prevention & Recovery and Reconstructive. The Prevention & Recovery segment offers products including rigid bracing, orthopedic soft goods, vascular systems, compression garments, and hot and cold therapy solutions, alongside recovery sciences products such as bone growth stimulators and electrical stimulators for clinical rehabilitation and sports medicine. The Reconstructive segment specializes in knee, hip, shoulder, elbow, foot, ankle, and finger implant products, as well as surgical productivity solutions. Additionally, Enovis provides Novastep, a minimally invasive surgery solution for foot and ankle procedures. The company's website is www.enovis.com. Enovis Corp is engaged in the production and distribution of medical devices aimed at improving patient outcomes through innovative technology and solutions in the health care industry. Enovis is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Enovis stock

EV/FCF (Enterprise Value to Free Cash Flow) of Enovis is 127.04 in 2025.

EV/FCF (Enterprise Value to Free Cash Flow) of Enovis changed from -37.59 to 127.04, representing a -437.96% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EV/FCF (Enterprise Value to Free Cash Flow) Enovis since 2006 – with annual values, charts, and detailed analysis.

The EV/FCF ratio measures the enterprise value relative to free cash flow. It captures the true cash-generating ability of a business.

To evaluate EV/FCF (Enterprise Value to Free Cash Flow)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/FCF (Enterprise Value to Free Cash Flow).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/FCF (Enterprise Value to Free Cash Flow)'s Enovis with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Enovis

All Key Metrics — Enovis